Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-β Gene1

@article{Shibata2006InductionOE,
  title={Induction of Efficient Antitumor Immunity Using Dendritic Cells Activated by Recombinant Sendai Virus and Its Modulation by Exogenous IFN-$\beta$ Gene1},
  author={Satoko Shibata and Shinji Okano and Yoshikazu Yonemitsu and Mitsuho Onimaru and Shihoko Sata and Hiroko Nagata-Takeshita and Makoto Inoue and Tsugumine Zhu and Mamoru Hasegawa and Yoichi Moroi and Masutaka Furue and Katsuo Sueishi},
  journal={The Journal of Immunology},
  year={2006},
  volume={177},
  pages={3564 - 3576}
}
Dendritic cell (DC)-based cancer immunotherapy has been paid much attention as a new and cancer cell-specific therapeutic in the last decade; however, little clinical outcome has been reported. Current limitations of DC-based cancer immunotherapy include sparse information about which DC phenotype should be administered. We here report a unique, representative, and powerful method to activate DCs, namely recombinant Sendai virus-modified DCs (SeV/DC), for cancer immunotherapy. In vitro… 
Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells.
TLDR
This is the first demonstration that non-transmissible SeV vector, SeV/dF, could be a DC-activator; DC/SeV/ dF-based cancer immunotherapy may, therefore, warrant further investigation.
Sustained and NK/CD4+ T Cell-Dependent Efficient Prevention of Lung Metastasis Induced by Dendritic Cells Harboring Recombinant Sendai Virus1
TLDR
These results are the first demonstration of efficient inhibition of lung metastasis via bolus administration of virally activated DCs that was sustained and NK/CD4+ cell-dependent, and may suggest a potentially new mechanism of DC-based immunotherapy for advanced malignancies.
Fas-deficient fully allogeneic dendritic cells administered via an intratumoral injection route show efficient antitumor effects in murine models.
TLDR
Intratumoral injection therapy using fully allogeneic DCs of which functional Fas is inhibited may be an alternative in clinical DC-based immunotherapy, under circumstances that do not allow the use of autologous DCs.
Sequential actions of immune effector cells induced by viral activation of dendritic cells to eliminate murine neuroblastoma.
TLDR
The combination of radiation and rSeV/DC therapy induces different effector cells, depending on the time point during treatment, which causes the tumor to increase in size from an early stage of treatment in the CD4+ and NK cell-depleted group to increased in size during treatment with γ-irradiation.
Induction of antitumor immunity against mouse carcinoma by baculovirus-infected dendritic cells
TLDR
It is shown that baculovirus-infected DCs induce antitumor immunity and pave the way for the use of this technique as an effective tool for DC immunotherapy against malignancies.
Antagonism of VEGF by Genetically Engineered Dendritic Cells Is Essential to Induce Antitumor Immunity against Malignant Ascites
TLDR
It is determined that the imbalance between the VEGF-A/vascular permeability factor and its decoy receptor, soluble fms-like tryrosine kinase receptor-1 (sFLT-1), was a major cause of MA resistance to dendritic cell (DC)-based immunotherapy.
Complete elimination of established neuroblastoma by synergistic action of γ-irradiation and DCs treated with rSeV expressing interferon-β gene
TLDR
A preclinical efficacy study to examine murine models and indicate that the combination of ts-rSeV/dF-mIFNβ-DCs with γ-irradiation is a hopeful strategy for the treatment of intractable neuroblastomas, warranting further investigation in the clinical setting.
Provision of Continuous Maturation Signaling to Dendritic Cells by RIG-I–Stimulating Cytosolic RNA Synthesis of Sendai Virus
TLDR
It is demonstrated in this study that the rSendai virus vector (SeV) is a novel and ideal stimulant, providing DC with a continuous maturation signal via viral RNA synthesis in the cytosol, resulting in full maturation of monocyte-derived DC(s).
Pathogen-related signal transduction pathways of dendritic cells: Perspectives for cancer immunotherapy
TLDR
Recent progress in the elucidation of the mechanisms of signal transduction pathways in DCs is reviewed and it is hoped that such inves- tigations will eventually lead to a variety of DC-based cancer immunotherapies.
Inactivated Sendai virus suppresses murine melanoma growth by inducing host immune responses and down-regulating β-catenin expression.
TLDR
This is the first report to show the effective inhibition of melanoma tumors by HVJ-E alone and the mechanism through which it induces antitumor immune responses and regulates important signal pathways for melanoma invasion.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide.
TLDR
The results strongly suggest that penicillin-killed Streptococcus pyogenes (OK-432) could be applied to develop an efficient cancer vaccine using DCs pulsed with tumor rejection peptides.
Strategies for antigen loading of dendritic cells to enhance the antitumor immune response.
TLDR
Correlation of in vitro data with the generation of protective immunity in vivo suggests the utility of irradiated tumor-primed DCs as a means to generate Protective immunity in patients with solid malignancies.
Enhanced Tumor-Specific Long-Term Immunity of Hemaggluttinating Virus of Japan-Mediated Dendritic Cell-Tumor Fused Cell Vaccination by Coadministration with CpG Oligodeoxynucleotides1
TLDR
The combination of DC-tumor FCs and CpG ODN is an effective and feasible cancer vaccine to prevent the generation and recurrence of cancers.
Self Antigens Expressed by Solid Tumors Do Not Efficiently Stimulate Naive or Activated T Cells: Implications for Immunotherapy
TLDR
The data show that the tumor did not spontaneously induce or maintain an activated CTL response, revealing a profound lack of immunogenicity in vivo, and repetitive immunizations are necessary for prolonged antitumor immunotherapy.
Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells.
TLDR
Results show that immunotherapy can succeed in the setting of advanced lymphoma if dendritic cells are restored and loaded with tumor antigens in situ at a single tumor site.
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
TLDR
Vaccination with autologous DCs generated from peripheral blood is a safe and promising approach in the treatment of metastatic melanoma and antigen-specific immunity was induced during DC vaccination.
Dendritic cell vaccination for cancer therapy
A growing list of defined tumor-antigens opens the way to antigen specific immunotherapy of cancer. However current approaches are often limited in their potential to induce an effective anti-tumor
Relevance of the Tumor Antigen in the Validation of Three Vaccination Strategies for Melanoma1
TLDR
The results strongly emphasize the relevance of the tumor Ag in the definition of immunotherapeutic strategies for cancer, and support the use of peptide-pulsed DC as cancer vaccine in humans.
Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
TLDR
Using the immunogenic C3 (H-2b) tumor model in B6 mice, tumor peptide-pulsed DC therapy resulted in the erradication of established d14 tumors and long-term survival in 100% of treated animals.
IL-12 Gene Therapy Is an Effective Therapeutic Strategy for Hepatocellular Carcinoma in Immunosuppressed Mice1
TLDR
Intratumoral mIL-12 gene therapy is a potent effective strategy not only to treat recurrences of HCC in liver transplantation, but also to treat solid malignant tumors in immunosuppressed patients with transplanted organ.
...
1
2
3
4
5
...